Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 5.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000097 | Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France] | Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs |
| 000103 | Ernest Choy [Royaume-Uni] ; Nick Freemantle [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Laurence Pollissard [France] ; Andreas Kuznik [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Erin Mangan [États-Unis] ; Paulo Carita [France] ; Thi-Minh-Thao Huynh [France] | Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses |
| 000110 | Noemi Muszbek [Royaume-Uni] ; Clare Proudfoot [Royaume-Uni] ; Marie Fournier [France] ; Chieh-I Chen [États-Unis] ; Andreas Kuznik [États-Unis] ; Zsofia Kiss [Royaume-Uni] ; Peter Gal [Hongrie] ; Kaleb Michaud [États-Unis] | Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs |
| 000171 | Vibeke Strand [États-Unis] ; Laure Gossec [France] ; Clare W. J. Proudfoot [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Matthew Reaney [Royaume-Uni] ; Sophie Guillonneau [France] ; Toshio Kimura [États-Unis] ; Janet Van Adelsberg [États-Unis] ; Yong Lin [États-Unis] ; Erin K. Mangan [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Gerd R. Burmester [Allemagne] | Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis |
| 000243 | Vibeke Strand [États-Unis] ; Matthew Reaney [Royaume-Uni] ; Chieh-I Chen [États-Unis] ; Clare W J. Proudfoot [Royaume-Uni] ; Sophie Guillonneau [France] ; Deborah Bauer [États-Unis] ; Erin Mangan [États-Unis] ; Neil M H. Graham [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Yong Lin [États-Unis] ; César Pacheco-Tena [Mexique] ; Roy Fleischmann [États-Unis] | Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors |
| This area was generated with Dilib version V0.6.34. |  |